ARTICLE | Company News

Medicines Co., SciClone deal

December 22, 2014 8:00 AM UTC

The Medicines Co. granted SciClone exclusive rights to promote cardiovascular drugs Cleviprex clevidipine and Angiomax bivalirudin in China. SciClone will be responsible for all pre- and post-launch commercialization, excluding Hong Kong and Macau. In addition to royalties, Medicines Co. is eligible to receive up to $50.5 million, including an undisclosed upfront payment, a product support service fee and milestones. Angiomax is under review by China Food and Drug Administration (CFDA). ...